ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

NCT04267939 | Terminated Phase 1 FDA Drug

• 2 other identifiers: 185952018-003930-34
• Study Type: interventional
• Target: 14
• Locations: 1 country
• Sites: 3

Brief Summary

The purpose of the study is to test how well patients with advanced solid tumors and ovarian cancer respond to treatment with elimusertib in combination with niraparib. In addition researchers want to find for patients the optimal dose of elimusertib in combination with niraparib, how the drug is tolerated and the way the body absorbs, distributes and discharges the drug. The study medication elimusertib works by blocking a substance produced by the body (ATR Kinase) which is important for the growth of tumor cells. Niraparib works by blocking a substance produced by the body (PARP enzymes) in a way that tumor cells can be killed, or made more susceptible to chemotherapy.

Conditions

Advanced Solid Tumors (Excluding Prostate Cancer); Ovarian Cancer

Outcome Measures

Primary Outcomes (6)

• Incidence of treatment emergent adverse events (TEAEs)

  Up to 30 days after the last administration of study intervention

• Severity of treatment emergent adverse events (TEAEs)

  Up to 30 days after the last administration of study intervention

• Incidence of treatment emergent serious adverse events (TESAEs)

  Up to 30 days after the last administration of study intervention

• Severity of treatment emergent serious adverse events (TESAEs)

  Up to 30 days after the last administration of study intervention

• Maximum tolerated dose (MTD): Frequency of Dose Limiting Toxicities (DLTs) at each dose level during the DLT observation period for Cycle 1

  Cycle 1, 28 days after first administration of study intervention

• Recommended Phase II dose (RP2D) of elimusertib

  Up to 30 days after last administration of study Intervention

Secondary Outcomes (10)

• Incidence of participants with complete response (CR)

  At baseline and at the start of every 2nd cycle (each cycle is 28 days) starting with Cycle 3, and at the start of every 4th cycle after Cycle 11 up to 24 months.

• Incidence of participants with partial response (PR)

  At baseline and at the start of every 2nd cycle (each cycle is 28 days) starting with Cycle 3, and at the start of every 4th cycle after Cycle 11 up to 24 months.

• Incidence of participants with stable disease (SD)

  At baseline and at the start of every 2nd cycle (each cycle is 28 days) starting with Cycle 3, and at the start of every 4th cycle after Cycle 11 up to 24 months.

• Incidence of participants with progressive disease (PD)

  At baseline and at the start of every 2nd cycle (each cycle is 28 days) starting with Cycle 3, and at the start of every 4th cycle after Cycle 11 up to 24 months.

• Objective response rate (ORR)

  At baseline and at the start of every 2nd cycle (each cycle is 28 days) starting with Cycle 3, and at the start of every 4th cycle after Cycle 11 up to 24 months.

Study Arms (6)

Dose escalation of elimusertib_Part A.1

EXPERIMENTAL

Dose escalation will initiate with Part A.1 in which niraparib is used at a lower fixed dose.

Drug: Elimusertib (BAY1895344); Drug: Niraparib

Dose escalation of elimusertib_Part A.2

EXPERIMENTAL

If the starting dose level in Part A.1 is tolerated, dose escalation in Part A.2 may be initiated on an optional basis. In Part A.2, niraparib is used at a higher fixed dose.

Drug: Elimusertib (BAY1895344); Drug: Niraparib

Dose expansion_sub-population 1_lower dose of niraparib

EXPERIMENTAL

MTDs and/or candidate RP2Ds for elimusertib used in combination with niraparib at a lower fixed dose. MTD: Maximum tolerated dose. RP2D: Recommended phase 2 dose.

Drug: Elimusertib (BAY1895344); Drug: Niraparib

Dose expansion_sub-population 2_lower dose of niraparib

EXPERIMENTAL

MTDs and/or candidate RP2Ds for elimusertib used in combination with niraparib at a lower fixed dose.

Drug: Elimusertib (BAY1895344); Drug: Niraparib

Dose expansion_sub-population 1_higher dose of niraparib

EXPERIMENTAL

MTDs and/or candidate RP2Ds for elimusertib used in combination with niraparib at a higher fixed dose.

Drug: Elimusertib (BAY1895344); Drug: Niraparib

Dose expansion_sub-population 2_higher dose of niraparib

EXPERIMENTAL

MTDs and/or candidate RP2Ds for elimusertib used in combination with niraparib at a higher fixed dose.

Drug: Elimusertib (BAY1895344); Drug: Niraparib

Interventions

Elimusertib (BAY1895344) DRUG

Elimusertib will be administered in 28-day cycles.

Dose escalation of elimusertib_Part A.1; Dose escalation of elimusertib_Part A.2; Dose expansion_sub-population 1_higher dose of niraparib; Dose expansion_sub-population 1_lower dose of niraparib; Dose expansion_sub-population 2_higher dose of niraparib; Dose expansion_sub-population 2_lower dose of niraparib

Niraparib DRUG

Niraparib will be administered in 28-day cycles.

Dose escalation of elimusertib_Part A.1; Dose escalation of elimusertib_Part A.2; Dose expansion_sub-population 1_higher dose of niraparib; Dose expansion_sub-population 1_lower dose of niraparib; Dose expansion_sub-population 2_higher dose of niraparib; Dose expansion_sub-population 2_lower dose of niraparib

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participant must be ≥ 18 years of age, at the time of signing the informed consent.
• Participants must have histologically confirmed diagnosis of the following indications as described below:
• Dose escalation (Part A): recurrent advanced solid tumors, excluding prostate cancer, who experienced disease progression after treatment with standard of care therapy for metastatic disease.
• Dose expansion (Part B): recurrent EOC, fallopian tube or primary peritoneal cancer
• Sub-population 1: participants PARPi naïve and with a platinum-resistant/refractory disease (recurrence with a PFI \< 6 months from last platinum-based regimen). Participants may not have had more than 3 prior therapies since the development of platinum resistance.
• Sub-population 2: participants with disease progression on PARPi (including niraparib), administered as maintenance as well active line of therapy. Participants must have not received further line of therapy after disease progression on PARPi.
• Participants in dose escalation (Part A) of the study will need to have tumor-associated DDR deficiency and/or CCNE1 gene amplification.
• \-- A homozygous deletion and/or a deleterious mutation in a gene reported to be involved in DNA repair and/or sensitive to ATRi's and/or PARPi's.
• Participants in dose expansion (Part B) of the study will need to have tumor associated DDR deficiency (Sub-population 1). Participants in Part B (Sub-population 2) are not enrolled based on the presence or absence of a particular biomarker.
• Participants must have disease progression and measurable disease, as defined by RECIST 1.1.
• Available archival tumor tissue ≤ 12 months old, otherwise a fresh baseline tumor biopsy should be obtained.
• ECOG PS of 0 to 1
• Life expectancy of at least 12 weeks
• Adequate bone marrow function as assessed by the following laboratory tests to be conducted within 7 (±2) days before the first dose of study intervention:
• Hemoglobin (Hb) ≥ 10 g/dL

You may not qualify if:

• Inability to swallow oral medication
• Known hypersensitivity to elimusertib and/or niraparib or excipients of the preparations or any agent given in association with this study
• History of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) diagnosis
• Ongoing or active uncontrolled infection (bacterial, fungal, or viral; e.g. hepatitis viral) of CTCAE grade ≥ 2 that requires systemic treatment
• Participants with HIV may be be ineligible depending on various parameters, but are not automatically excluded.
• Immunocompromised participants (e.g. diagnosis of immunodeficiency or ongoing immunosuppressive therapy)
• Pleural effusion or ascites that causes respiratory compromise (CTCAE grade ≥ 2 dyspnea)
• Active HBV or HCV infection that requires treatment.
• Moderate or severe hepatic impairment, i.e. Child Pugh Class B or C
• Participants with significant cardiovascular disease and/or relevant findings meeting the below criteria are excluded:
• History of cardiac disease: congestive heart failure NYHA class \> II, unstable angina (angina symptoms at rest), new-onset angina (within the past 6 months before study entry), myocardial infarction within the past 6 months before study entry, or cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers, calcium channel blockers, and digoxin are permitted).
• Clinically relevant findings in the ECG such as a second- or third-degree atrioventricular block, prolongation of the QRS complex ≥ 120 ms, or prolongation of the of the QTc interval (Fridericia) over 450 ms unless agreed otherwise between the investigator and the sponsor's medically responsible person. QTc \> 450 ms detected in 2 or more time points within a 24-hour period are excluded.
• Clinically significant arterial hypertension despite optimal medical management (per investigator´s opinion). Clinically significant hypertension defined as systolic blood pressure above 150 mmHg and/or diastolic blood pressure above 90 mmHg, despite optimal medical management. For participants taking antihypertensive medication, blood pressure should be stable/ controlled for more than 7 days before first dose of study medication.
• Previous treatment with an ATR Inhibitor
• Participants in Part A and Part B (Sub-population 2): Previous treatment with known or putative PARPi, if discontinued for CTCAE grade ≥ 3 AEs or CTCAE grade ≥ 3 hypersensitivity to PARPi. Participants in Part B Sub-population 1 must not have received prior PARPi treatment.

Sponsors & Collaborators

• Bayer: lead
• GlaxoSmithKline: collaborator

Study Sites (3)

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States

Location

Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States

Location

University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location

Related Publications (1)

• Smith G, Alholm Z, Coleman RL, Monk BJ. DNA Damage Repair Inhibitors-Combination Therapies. Cancer J. 2021 Nov-Dec 01;27(6):501-505. doi: 10.1097/PPO.0000000000000561.

  PMID: 34904813 DERIVED

MeSH Terms

Conditions

Ovarian Neoplasms

Interventions

BAY 1895344; niraparib

Condition Hierarchy (Ancestors)

Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders

Study Officials

• Bayer Study Director

  Bayer

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 11, 2020
• First Posted: February 13, 2020
• Study Start: February 26, 2020
• Primary Completion: December 1, 2023
• Study Completion: December 1, 2023
• Last Updated: December 21, 2023

Record last verified: 2023-12

Data Sharing

• IPD Sharing: Will not share

Locations

US (3)